Empagliflozin (JARDIANCE®) go beyond lowering A1C | Boehringer Ingelheim

Boehringer Ingelheim

For Healthcare Professionals

Logout

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim

Therapeutic Area
Therapeutic Area

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our Focus articulates who we are and what we strive for, how we work and what we want to achieve.

Section Overview

Therapeutic Area

Section Overview

Cardiovascular

Metabolic

Inflammation

Respiratory
Products
Products

Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.

See all products

Products

See all products
Resources
Contact
Logout

Boehringer Ingelheim

Efficacy
CV Risk Protection
EMPA-REG Outcome Trial
Guidelines
Expert's video
CHAMPS
Prescribing Information

Empagliflozin (JARDIANCE®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease

updated banner-jardiance-new

Empagliflozin (JARDIANCE)'s Consistent CV and Renal Benefits in HFrEF

04/07/2022 | Document ID: PC-PH-103702

Jardiance-hf

Jardiance 10mg is Safe in Heart failure

Empagliflozin (JARDIANCE) 10mg improves the quality of life in HFrEF

Empagliflozin (JARDIANCE)'s Consistent CV and Renal Benefits in HFrEF

RELATED CONTENT

02:46

Empagliflozin (JARDIANCE) 10mg improves the quality of life in HFrEF

Watch now Opens in new tab

01:32

Jardiance 10mg is Safe in Heart failure

Watch now Opens in new tab

Production Date: July 2022

Home
Metabolic
Empagliflozin
Jardiance-hf
Empagliflozin (JARDIANCE)'s Consistent CV and Renal Benefits in HFrEF

Sitemap

Therapeutic Area

Resources
- Videos
- Clinical studies

BI logo

Privacy
Terms of use
Sitemap
Contact

Copyright © 2025 Boehringer Ingelheim (Philippines), Inc. All rights reserved. Use of this Site is subject to the Terms of Use and Privacy Statement. Prepared June 2025